TREATMENT OF
VIRAL HEPATITIS & HCC:
MANAGEMENT OF CHRONIC HEPATITIS B:
BEYOND THE GUIDELINES
THE NEXT PHASE OF HEPATITIS C THERAPY:
WHEN, HOW AND WHOM TO TREAT?
ADVANCES IN DIAGNOSIS &
TREATMENT OF HCC

JUNE 12-14, 2014
ROYAL BEACH HOTEL EILAT

SCIENTIFIC PROGRAM
THURSDAY • JUNE 12, 2014 • 12:30-19:30

12:30

Opening remarks
Prof. Rifaat Safadi
Chairman of the Israel Association for the Study of the Liver

SESSION 1A  12:30-13:40

EPIDEMIOLOGY & PUBLIC HEALTH IN HBV
Chairman: Prof. Rifaat Safadi & Prof. Ziv Ben Ari

12:30-12:55
Hepatitis B in 2014: Therapy beyond Guidelines
Prof. Geoffrey Dusheiko, MD, MB,BCh
Professor of Medicine, The Royal Free Hospital and University
College School of Medicine, London, UK.

13:05-13:25
HBsAg Quantification for the management & treatment of HBV infection
Prof. Philippe Halton, MD,Phd
Director of Virological Laboratory & Infection Diseases, Laboratoire ALPHABIO, Hospital Ambroise Pare, Marseille, France

13:30-13:38
HBV Vertical Transmission: The Real Life
Prof. Rifaat Safadi
N. Saed1, M. Hakim2, Y. Nijim2, N. Farah1, J. Jamalia3, T. Nuser3,
N. Natur4, M. Mahamid1, J. Amer, R. Dajani5, W.H. Gerlich6,
D. Glebe6, R. Safadi1, 4

1Holy Family Hospital, 2Nazareth Hospital & 3French Hospital, Nazareth. 4Liver Unit, Institute of Gastroenterology, Hadassah-Hebrew University Hospital & 5Dajani Hospital, Jerusalem. Israel. 6National Reference Center for Hepatitis B & D viruses, Institute of Medical Virology, Giessen Germany

SESSION 1B  13:40-14:30

EPIDEMIOLOGY & PUBLIC HEALTH IN HCV
Chairman: Prof. Emanuel Sikuler & Prof. Assy Nimer

13:40-13:55
HCV-Viral Life Cycl: Targets for Direct Anti Virals
Prof. Ran Tur Kasp
Beilinson Hospital, Israel
13:55-14:00  
**Inhibition of HCV infection by CD14 targeting**  
L. Bachmetov  
L. Bachmetov, B. Bensimhon, R. Zemel, R. Tur-Kaspa  
1 Molecular Hepatology Research Laboratory, 2 Department of Medicine D and Liver Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel

14:00-14:25  
**Natural History of HCV: Who Requires Therapy?**  
Dr. Ashley Brown  
Liver Unit, St. Mary’s Hospital, UK

14:30-15:00  
**Coffee Break**

**SESSION 2  15:00-16:45**  
**SCREENING & DIAGNOSIS OF HCC**  
Chairman: Dr. Michal Carmi & Dr. Marius Braun

15:00-15:05  
**Invasiveness of HCC induced by Hepatitis viruses**  
Liat Ninio  
Liat Ninio, Ateret Davidovich, Joel Alter, Hava Gil-Henn, Meital Gal-Tanamy  
Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel

15:07-15:32  
**Imaging Techniques in the Diagnosis & Staging of HCC: The Hepatologist’s Perspective?**  
Dr. Sangro Bruno, Spain, MD, PhD,  
Director of the Liver Unit - Clinica Universidad de Navarra,  
Aggregate Professor of Medicine at the University of Navarra  
School of Medicine Spain

15:37-15:52  
**Contrast Enhanced Ultrasound for HCC**  
Dr. Liat Appelbaum  
Hadassah, Israel

16:02-16:07  
**Infiltrating monocyte-derived macrophages & resident kupffer cells display different ontogeny & functions in acute liver injury**  
Dr. Ehud Zigmond  
Ehud Zigmond, Shany Samia-Grinberg, Metsada Pasmanik-Chor, Eli Brazowski, Oren Shibolet, Zamir Halpern, Chen Varol
16:12-16:17 The mTOR Pathway is involved in Amiodarone Hepatotoxicity
Noam Erez
Noam Erez¹, Raya Cohen¹, Dotan Uzi², Viviana Scaiewicz², Boaz Tirosh², Oren Shibolet¹.
¹Liver Unit, Department of Gastroenterology Tel Aviv Medical Center, Tel-Aviv, Israel. ²Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

16:19-16:44 Decision Making Process in The Health Basket
Prof. Moshe Leshno
Sourasky Medical Center, Israel

16:50-17:00 Coffee Break

17:00-19:15 SATELLITE SYMPOSIA

17:00-17:45 Review of clinical data of IFN, Ribavirin, 1st generation Protease Inhibitors
Prof. Safadi Rifaat
Chairman of the Israeli Association for the Study of Liver. Director of Liver Unit, Institute of Gastroenterology and Liver Diseases division of Medicine, Hadassah Medical Center.

HCV - Budget impact of next generation treatments
Prof. Oren Ran
Professor of Medicine and Gastroenterology. Head of the Institute of Gastroenterology and Liver Diseases, Department of Medicine, Hadassah. University Hospital, Ein Kerem.
HCV - The payer view of next generation treatments
Dr. Oren Shavit
Chief Pharmacist at ‘Meuhedet’ Sick fund.

HCV - Interactive Q&A session
Prof. Ziv Ben-Ari
Director Liver Disease Center
Sheba Medical Center, Tel Hashomer

Panel Discussion on the next generation treatments
Panel Members:
Prof. Safadi Rifaat
Prof. Oren Ran
Dr. Oren Shavit

17:45-18:30

Review of present & future generics with Hep B arena
Prof. Eli Zuckerman
Director of the Liver Unit, Carmel University Medical Center, Technion
Faculty of Medicine, Haifa, Israel

The HMO’s perspective
Dr Oren Shavit
Chief Pharmacist at ‘Meuhedet’ Sick fund

The legal aspect
Zohar Yahalom, Adv.
Zohar Yahalom Law Office
Azrieli Center - Beit Shimon

HBV Interactive Q&A session
Dr. Oren Shibolet
Director of the Liver Unit, Department of Gastroenterology
Tel-Aviv Sourasky Medical Center and Tel-Aviv University

Panel Discussion
Panel Members:
Prof. Eli Zuckerman
Zohar Yahalom Adv.
Dr. Oren Shavit
Dr. Oren Shibolet
18:30-19:15

**The clinical aspects of treating the hard to cure CHC patients**

Dr. Ashley Brown
Liver Unit, St. Mary’s Hospital, UK

**IFN free therapies for the treatment of HCV - High cure rate - Interactive session + voting system**

Dr. Ashley Brown
Liver Unit, St. Mary’s Hospital, UK
PARALLEL SESSION FOR NURSES

14:00-17:30

14:00-14:40

ITZRUBAL ROOM - FLOOR -2
Health Issues in Patients with Chronic Liver Disease
Dr. Hanny Yeshua
Liver Unit, Tel-Aviv Medical Center and Tel-Aviv University

14:40-15:20

Great Hopes in an Age of Uncertainty
Dr. Oren Shibolet
Director of the Liver Unit, Department of Gastroenterology,
Tel-Aviv Medical Center and Tel-Aviv University

15:20-15:40

Break

15:40-16:10

“Make Hep C History”
Patient’s videos

Patient Undergoing Biopsy: Acceptance, Preparation & Follow-up
Orly Azulay
Chief Research Nurse/Coordinator, Liver Unit Clinical Research Unit, Carmel Medical Center

Assessment of Quality of Life in Cirrhotic Out-Patients with Ascites – an Interventional Program
Keren Tsaraf
Chief Nurse, Liver Diseases Center of Sheba Tel-Hashomer

16:10-16:30

Experta – Janssen’s “Digital Tool-Box”
Yaffit Levy
Business Unit Manager, Janssen

16:30-17:30

“Emotional Intelligence with and for patients - The rational within the Emotional”
Einat Glazer, Ph.D
Organizational psychologist, Renma

Sponsored & Organized by:
08:00  Opening Remarks
Prof. Rifaat Safadi
Chairman of the Israeli Association for the Study of Liver

SESSION 1
08:00-09:35
REVOLUTION IN HCV ERADICATION
Chairman: Prof. Rifaat Safadi & Prof. Ran Oren

08:00-08:25  Hepatitis C - New Treatment, New Prospects & New Challenges
Prof. Geoffrey Dusheiko, MD, MB,BCh
Professor of medicine  The Royal Free Hospital and University
College School of Medicine, London, UK.

08:30-08:55  DAA’s in Phase III: The near Future in IFN Free Regimen
Prof. Tarik Asselah, MD, PhD
Hôpital Beaujon & University of Paris Diderot, France.

09:00-09:15  1st Generation PI’s in HCV: The Real Life
Prof. Eli Zukerman
Carmel Medical Center, Israel

09:20-09:25  Telaprevir or Boceprevir-based triple therapy for HCV in liver
transplanted patients
Dr. Salah Daher
Yaari S, Merhav H, Khalaileh A, Rowe M, Daher S, Safadi R
Hadassah Medical Center

09:30-09:35  Fitting individual HCV antiviral treatment to genotype 1 patients
according to their innate response dynamics
Dr. Yoav Smith
Yoav Smith1, Yoav Lurie 5, Inna Gafanovitch 5, Shimon Shteingart 5,
Ella Weitzman 3, Shlomo Pundak 6, Ziv Ben-Ari 2,3,4
1Genomic Data Analysis Unit, Hebrew University Medical School,
Jerusalem, 2Liver Research Laboratory, 3Liver Disease Center,
Sheba Medical Center, Ramat Gan, 4Sackler School of Medicine,
Tel Aviv University, Tel Aviv, 5Liver Unit, Shaare Zedek ,Medical
Center ,Jerusalem, Israel , 6Genefron,Jerusalem ,Israel
SESSION 2

09:40-16:45
UPDATE IN MANAGEMENT OF HCC

Chairman: Dr. Yaacov Maor & Prof. Yaacov Baruch

09:40-09:45
A liver-specific tumor suppressor miR-122* that targets Mdm2
Alina Simerzin
Alina Simerzin1, Elina Zorde-Khvalevsky1, Mila Rivkin1, Revital Adar1, Chofit Chai1, Tania Roskams2, Olivier Govaere2, Moshe Oren3, Hilla Giladi1, Eithan Galun1

1The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
2Department of Pathology and the Laboratory of Morphology and Molecular Pathology, University Hospitals, University of Leuven, Leuven, Belgium, 3Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

09:50-10:15
Radioembolization for HCC
Dr. Sangro Bruno, Spain, MD, PhD,
Director of the Liver Unit - Clinica Universidad de Navarra,
Aggregate Professor of Medicine at the University of Navarra
School of Medicine Spain

10:15-10:40
Coffee Break

SESSION 3

10:45-11:15
HCV GUIDELINES

Chairman: Dr. Yoav Lurie

EASL Guidelines for HCV Therapy
Prof. Tarik Asselah, MD, PhD
Hôpital Beaujon & University of Paris Diderot, France.
SESSION 4

11:20-12:30
SHORT ABSTRACT PRESENTATIONS
Chairman: Dr. Jorge-Shmuel Delgado, Dr. Shibolet, Dr. Johnny Amer & Prof. Rafi Bruck

Opening Remarks
IaSL GB

Can histomorphometric findings predict response to antiviral therapy in patients with chronic HCV infection?
Dr. Tarek Saadi,
Tarek Saadi\textsuperscript{1,2,4} MD, Mayson Darawshi\textsuperscript{4} MD, Amir Klein\textsuperscript{1,2,4} MD, Edmond Sabo\textsuperscript{3,4} MD, Yaacov Baruch\textsuperscript{1,4} MD
\textsuperscript{1}Liver Unit, \textsuperscript{2}Department of Gastroenterology, \textsuperscript{3}Department of Pathology, Rambam Health Care Campus, Haifa, Israel. \textsuperscript{4}The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Budesonide in Granulomatous Hepatitis
Dr. Mahmoud Mahamid
Mahamid Mahmoud\textsuperscript{1,2}, Rami Ghantous\textsuperscript{1,3}, Rifaat Safadi\textsuperscript{1,3}
\textsuperscript{1}The Nazareth Holy Family Hospital, \textsuperscript{2}Shaarei Zedek Hospital and \textsuperscript{3}Hadassah Medical Center, Jerusalem

Non Alcoholic Fatty Liver Disease (NAFLD) may induces Portal Hypertension without associated Liver Fibrosis
Prof. Nimer Assy
Kapninov I, Farah R, Gilbstein N, Djibre A, Grosovski M, Bar Guy N, Assy N.
Liver Unit, Ziv Medical Center. Faculty of Medicine at Galilee, Bar Ilan University, Safed, Israel
Clinical practices in the management of patients with acute liver failure: Results of an international multi-center Survey

Liane Rabinowich

Liane Rabinowich¹, Sari Ziv¹, Julia Wendon², William Bernal²†, Oren Shibolet¹† For the EUROALF group

¹ Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center and Tel-Aviv University, Tel-Aviv, Israel.
² Liver Intensive Therapy Unit, Institute of Liver Studies, King’s College Hospital, London, UK.
† These authors contributed equally.

Does Medical Specialty Impacts Recommendations of Multi-disciplinary Team (MDT)?

Dr. Yoram Menachem

Yoram Menachem¹, Moshe Leshno¹, Isac Kori², Ada Kessler³, Ravit Geva⁴, Oren Shibolet¹, Menahem Ben-Haim⁵.

¹ Liver unit, Department of Gastroenterology, ² Interventional Radiology Unit, ³ Radiology department, ⁴ Oncology department, ⁵ Liver Surgery Unit, Tel-Aviv Medical Center, Tel-Aviv, Israel.

הטיפול המשולש מבוסס אינטרפרון ריבויורן וממעב פרוטאז בחולי הפט铆טיס-סיכום נסיון טיפולי עשיר במרכז הרפואי שלושה בדרום הארץ.

**Secondary Sclerosing Cholangitis Following Major Burn**

Dr. Weitzman E

Weitzman E¹, Haviv-Yadid Y², Livingstone D⁴, Cohen-Ezra O¹⁶, Pappo O², Inbar Y⁴, Amitai M⁴, Ben-Haim M⁶, Vider-Faysnd Anat⁵, Haik Y⁶, Ben Ari Z¹⁷

¹Liver Disease Center, ²Intensive Care Unit, ³Department of Pathology, ⁴Department of Radiology, ⁶Department of Plastic Surgery, ⁶Infectious Disease Unit, Sheba Medical Center, Ramat Gan and ⁷Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

**Syphilitic Hepatitis in patients with Human Immunodeficiency Virus (HIV)-Infected Patients**

Dr. Oren Shibolet

Liane Rabinowich¹, Eugene Katchman², Liat Mlynarsky¹, Oren Shibolet¹, Dan Turner²

¹Liver Unit, Department of Gastroenterology, Tel-Aviv Sourasky Medical Center, ²Krusaid Cobler AIDS Center, Infectious Diseases Unit, Tel-Aviv Sourasky Medical Center

**Tregs expansion & reversal of portal vein CD4+/CD8+ distribution, A novel inflammatory portal hypertension**

Dr. Tomer Adar

Tomer Adar¹, Yair Edden², Shimon Shteingart¹, Mahmud Mahamid¹, Ellen Broide ³, Ariella Bar-Gil Shitrit¹, Eran Goldin¹

¹Gastroenterology department, Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem Israel, ²Department of General Surgery, Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem Israel, ³Flow cytometry unit, Department of immunology, Shaare Zedek Medical Center, Jerusalem Israel
NLG4-/- mice showed a decreased inflammatory & fibrotic profile, associated with NK cells activation
Dr. Johnny Amer
Johnny Amer, Sarit Doron, Ahmad Salhab, Nadav Ilani, Rifaat Safadi
Liver Unit, Institute of Gastroenterology and Liver Diseases. Hadassah-Hebrew University Hospital, Jerusalem.

Evaluation of etiology dependent epigenetic alteration profiles and biomarkers in Hepatocellular carcinoma
Shira Perez
Shira Perez, Roi Feingersh, Ateret Davidovich, Itay Onn, Salomon Stemmer, Izhak Haviv and Meital Gal-Tanamy
Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel

Endobarrier Improves Hepatic Parameters of NAFLD in Obese Uncontrolled T2DM Patients
Dr. Cohen-Ezra O
Cohen-Ezra O, Segal-Lieberman G, Lang A, Lahav M,
Klienbaum Y, kacerginsky S, Tsaraf K, Ben Ari Z
1Liver Disease Center, 2Endocrine Institute, 3Gastroenterology Institute, 4Department of Radiology, Sheba Medical Center, Tel Hashomer, Ramat Gan, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Sustained virological response with intravenous silibinin
Dr. H. Dahari
1Division of Hepatology, Loyola University Medical Center, Maywood, IL, 2Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States, 3Digestive
Disease Institute, 4Liver Unit, Digestive Disease Institute, Shaare Zedek Medical Center, Jerusalem, Israel, 5Rottapharm | Madaus, Monza, Italy, 6Nursing Division, 7Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.

Treatment of HCV in the Elderly - Does It Impact Life Expectancy? - A Decision Analysis
Dr. Maor Y
Maor Y, Malnick SDH, Melzer E, Leshno M
Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Rehovot, Israel; Department of Internal Medicine C, Kaplan Medical Center, Rehovot, Israel; Faculty of Management and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
SESSION 5

12:30-12:55
HCV INDIVIDUALIZATION
Chairman: Dr. Yona Kitay-Cohen

12:30-12:55
Individualization of HCV Therapy in the New Era
Prof. Philippe Halfon, MD,Phd
Director of Virological Laboratory & Infection Diseases, Laboratoire ALPHABIO, Hospital Ambroise Pare, Marseille, France

13:00-14:00
Business meeting with the IaSL Governing Board
Prof. Rifaat Safadi
Dr. Michal Carmial
Dr. Yaacov Maor
Dr. Yoav Lurie
Dr. Jorge-Shmuel Delgado